Nesiritide Acetate

Product Name:Nesiritide Acetate

Form:Acetate salt

Purity:90%

Storage:-20^oC

Cas No:114471-18-0

Molar Mass:3524.1

Chemical Formula:C145H248N50O44S4

Synonyms:natriureticpeptide; BNP-32

IUPAC Name:acetic acid;(3S)-3-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(4R,7S,13S,16R)-16-[[2-[[(2S)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-13-benzyl-7-(3-carbamimidamidopropyl)-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carbonyl]amino]acetyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid??

SMILES:CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CCCNC(=N)N)CC3=CC=CC=C3)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CO)N.CC(=O)O

InChIKey:FJULFJFRGUHITK-INJFIXSDSA-N

InChI:InChI=1S/C143H244N50O42S4.C2H4O2/c1-13-76(10)112(137(232)180-86(36-26-48-161-143(155)156)122(217)183-93(56-109(206)207)128(223)178-88(40-50-236-11)124(219)173-81(30-17-20-42-144)119(214)174-83(32-19-22-44-146)125(220)190-111(75(8)9)136(231)184-91(53-73(4)5)127(222)176-84(34-24-46-159-141(151)152)121(216)175-85(35-25-47-160-142(153)154)123(218)185-94(139(234)235)55-78-57-157-71-167-78)192-132(227)99(68-199)188-131(226)98(67-198)187-130(225)97(66-197)186-129(224)96(65-196)171-107(204)61-163-114(209)90(52-72(2)3)169-105(202)59-166-117(212)100-69-238-239-70-101(133(228)182-92(54-77-28-15-14-16-29-77)115(210)164-58-104(201)168-80(118(213)189-100)33-23-45-158-140(149)150)172-108(205)62-165-116(211)95(64-195)170-106(203)60-162-113(208)87(38-39-103(148)200)181-135(230)110(74(6)7)191-126(221)89(41-51-237-12)177-120(215)82(31-18-21-43-145)179-134(229)102-37-27-49-193(102)138(233)79(147)63-194;1-2(3)4/h14-16,28-29,57,71-76,79-102,110-112,194-199H,13,17-27,30-56,58-70,144-147H2,1-12H3,(H2,148,200)(H,157,167)(H,162,208)(H,163,209)(H,164,210)(H,165,211)(H,166,212)(H,168,201)(H,169,202)(H,170,203)(H,171,204)(H,172,205)(H,173,219)(H,174,214)(H,175,216)(H,176,222)(H,177,215)(H,178,223)(H,179,229)(H,180,232)(H,181,230)(H,182,228)(H,183,217)(H,184,231)(H,185,218)(H,186,224)(H,187,225)(H,188,226)(H,189,213)(H,190,220)(H,191,221)(H,192,227)(H,206,207)(H,234,235)(H4,149,150,158)(H4,151,152,159)(H4,153,154,160)(H4,155,156,161);1H3,(H,3,4)/t76-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,110-,111-,112-;/m0./s1

Sequence:SPKMVQGSGCFGRCGLGSSSSIRDMKKVLRRH

Application:Nesiritide Acetate is a recombinant human B-type natriuretic peptide (BNP) used for the treatment of acute decompensated heart failure (ADHF). It exerts vasodilatory, natriuretic, and diuretic effects, reducing cardiac preload and afterload while improving cardiac output. Nesiritide works by activating guanylate cyclase receptors, leading to increased cGMP levels, which promote vascular smooth muscle relaxation and fluid balance regulation. Although its use in heart failure has declined due to mixed clinical outcomes, current research is exploring its potential in renal protection, hypertension, and pulmonary arterial hypertension (PAH), positioning it as a candidate for broader cardiovascular and renal applications.

Current Research:Nesiritide Acetate is a recombinant B-type natriuretic peptide (BNP) that mimics the endogenous BNP released by cardiac ventricles in response to volume overload and heart failure. It has been used primarily for acute decompensated heart failure (ADHF) treatment, but its clinical applications have been debated due to inconsistent trial outcomes. However, emerging research suggests potential uses in renal protection, hypertension, and pulmonary vascular diseases. Acute Decompensated Heart Failure (ADHF) Treatment Nesiritide was initially approved for ADHF treatment due to its vasodilatory and natriuretic effects, but subsequent clinical trials have questioned its effectiveness. Hemodynamic benefits: Nesiritide reduces pulmonary capillary wedge pressure (PCWP), systemic vascular resistance (SVR), and right atrial pressure, leading to improved cardiac output. Symptomatic relief: Some studies show that Nesiritide reduces dyspnea (shortness of breath) and congestion in ADHF patients. Controversy over mortality and renal effects: Large-scale trials (e.g., ASCEND-HF) raised concerns about potential worsening of renal function and no significant mortality benefit, leading to a decline in its routine use. Renal Protection and Acute Kidney Injury (AKI) Given its natriuretic and renal vasodilatory properties, Nesiritide is being investigated for renal protection in heart failure and perioperative settings. Prevention of contrast-induced nephropathy (CIN): Research is exploring whether Nesiritide can reduce kidney injury in patients undergoing contrast-enhanced imaging. Cardiorenal syndrome treatment: Nesiritide??s ability to enhance diuresis while preserving renal function makes it a candidate for managing heart failure-related kidney dysfunction. Perioperative AKI prevention: Studies are evaluating Nesiritide??s role in preserving renal perfusion during cardiac surgeries and high-risk surgical procedures. Pulmonary Hypertension and Cardiovascular Research Beyond heart failure, Nesiritide is being explored for vascular and pulmonary circulatory diseases. Pulmonary arterial hypertension (PAH): Research suggests that BNP analogs like Nesiritide may help reduce pulmonary vascular resistance and improve right ventricular function in PAH patients. Hypertension treatment: Nesiritide??s vasodilatory effects are being assessed for resistant hypertension, particularly in patients with heart failure and renal comorbidities. Ischemia-reperfusion injury protection: Some studies suggest that Nesiritide may reduce myocardial damage in patients undergoing cardiac bypass surgery. Neurohormonal Modulation and Metabolic Research Given its role in fluid balance and blood pressure regulation, Nesiritide is being investigated in neurohormonal modulation and metabolic disorders. Diabetes and metabolic syndrome: Preliminary studies suggest that BNP levels correlate with insulin sensitivity and metabolic homeostasis, prompting research into Nesiritide??s effects on glucose metabolism and lipid regulation. Neuroprotective effects: Research is exploring Nesiritide??s potential role in reducing neuroinflammation and improving cerebral circulation in conditions like stroke and vascular dementia. Emerging Research Areas Sepsis and critical care: Nesiritide??s effects on vasodilation and inflammatory modulation are being studied in septic shock and critical illness. Heart transplant and mechanical circulatory support: Research is exploring BNP analogs in improving cardiac function and preventing post-transplant rejection. Lymphatic and endothelial function regulation: Some experimental studies suggest Nesiritide may modulate endothelial permeability, with potential applications in vascular medicine and chronic venous diseases. While its role in acute heart failure remains debated, ongoing research into Nesiritide??s renal, vascular, metabolic, and neuroprotective effects may redefine its therapeutic applications beyond cardiology.

Reference:Rao, L. S., Niphadkar, M. P., Paliwal, D., Shekhawat, R., Khare, A. G., Uma, S., ... & Zawar, S. (2011). Expression, purification, and characterisation of nesiritide using an E. coli expression system.?Biotechnology and bioprocess engineering,?16(4), 688-697.